Drug:
Reaction: HOSPITALISATION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555386 |
US |
1 | |
Hospitalisation, |
||||
BLINATUMOMAB, |
||||
| 2 | 26555522 |
US |
1 | |
Hospitalisation, Dyspnoea, Therapy change, Device use issue, Product dose omission issue, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 3 | 26555702 |
CA |
61 | 2 |
Infusion related reaction, Pulmonary oedema, Discomfort, Hypertension, Hospitalisation, |
||||
AMIVANTAMAB-VMJW, AMIVANTAMAB-VMJW, |
||||
| 4 | 26555956 |
US |
79 | 2 |
Hospitalisation, |
||||
POMALIDOMIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CALCIUM, ROSUVASTATIN, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, FISH OIL, GABAPENTIN, HYDRALAZINE HYDROCHLORIDE, PANTOPRAZOLE, LEVOTHYROXINE SODIUM, ALBUTEROL SULFATE, VITAMIN C, ERGOCALCIFEROL, RIFAXIMIN, |
||||
| 5 | 26555999 |
CA |
56 | |
Hospitalisation, Antiphospholipid syndrome, Weight decreased, Night sweats, Off label use, |
||||
INFLIXIMAB-DYYB, |
||||
| 6 | 26556095 |
CA |
60 | |
Hospitalisation, Fatigue, Nephrolithiasis, Enterococcus test positive, Urosepsis, Escherichia infection, Urinary tract infection, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, SULFASALAZINE, |
||||
| 7 | 26556127 |
CA |
1 | |
Hospitalisation, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 8 | 26556271 |
CA |
||
Hospitalisation, Embolism, Vasculitis, |
||||
UPADACITINIB, |
||||
| 9 | 26556368 |
US |
60 | 1 |
Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 10 | 26556769 |
ZA |
66 | 2 |
Mental disorder, Syncope, Hospitalisation, Chills, Appetite disorder, Memory impairment, Blood glucose abnormal, |
||||
INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 11 | 26556809 |
US |
1 | |
Hospitalisation, |
||||
GLYCEROL PHENYLBUTYRATE, |
||||
| 12 | 26556843 |
CA |
1 | |
Hospitalisation, |
||||
BLINATUMOMAB, |
||||
| 13 | 26557358 |
US |
65 | 2 |
Hospitalisation, Product use issue, |
||||
| 14 | 26557838 |
US |
79 | 1 |
Hospitalisation, Product availability issue, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 15 | 26557897 |
CA |
59 | 2 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 16 | 26557898 |
US |
42 | 1 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 17 | 26557983 |
JP |
||
Hospitalisation, Condition aggravated, |
||||
STIRIPENTOL, STIRIPENTOL, |
||||
| 18 | 26557992 |
CO |
71 | 2 |
Diarrhoea, Somnolence, Hypotension, Hospitalisation, Decreased appetite, Gait disturbance, General physical health deterioration, Decreased immune responsiveness, Aphthous ulcer, Dysarthria, Haemoglobin decreased, Abdominal discomfort, |
||||
PANITUMUMAB, |
||||
| 19 | 26558178 |
US |
1 | |
Hospitalisation, |
||||
CANNABIDIOL, CANNABIDIOL, CANNABIDIOL, CANNABIDIOL, |
||||
| 20 | 26558586 |
US |
2 | |
Hospitalisation, |
||||
SEMAGLUTIDE, |
||||
| 21 | 26558887 |
AU |
1 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 22 | 26559151 |
US |
74 | 2 |
Hospitalisation, |
||||
ETANERCEPT, |
||||
| 23 | 26559155 |
CA |
79 | |
Hospitalisation, Pain in extremity, Peripheral swelling, Gait disturbance, Intentional product use issue, |
||||
USTEKINUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 24 | 26559272 |
US |
||
Hospitalisation, Off label use, |
||||
BETAINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CANDESARTAN, DULOXETINE HYDROCHLORIDE, DULOXETINE, HYDROXYZINE, HYOSCYAMINE SULFATE, METOPROLOL TARTRATE, METOPROLOL, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, LASMIDITAN, CARISOPRODOL, THYROID, PORCINE, |
||||
| 25 | 26559356 |
US |
69 | 1 |
Hospitalisation, |
||||
POMALIDOMIDE, |
||||
| 26 | 26559364 |
GB |
1 | |
Hospitalisation, |
||||
CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, |
||||
| 27 | 26559365 |
GB |
2 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 28 | 26559428 |
CN |
1 | |
Hospitalisation, |
||||
| 29 | 26559432 |
EU |
34 | 2 |
Hospitalisation, Treatment noncompliance, |
||||
CLOZAPINE, CLOZAPINE, |
||||
| 30 | 26559493 |
CA |
46 | 2 |
Hospitalisation, Neutropenia, |
||||
CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, |
||||
| 31 | 26559601 |
49 | ||
Hospitalisation, |
||||
FINGOLIMOD LAURYL SULFATE, |
||||
| 32 | 26559686 |
GB |
47 | 1 |
Hospitalisation, |
||||
BRODALUMAB, |
||||
| 33 | 26559950 |
US |
61 | 2 |
Hospitalisation, Pancreatic carcinoma, Fatigue, |
||||
PANCRELIPASE, |
||||
| 34 | 26560300 |
US |
83 | 1 |
Hospitalisation, |
||||
ABATACEPT, |
||||
| 35 | 26560305 |
US |
62 | 1 |
Hospitalisation, Product use in unapproved indication, |
||||
OXYCODONE, FINASTERIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CHLORPHENIRAMINE MALEATE, OXYCODONE HYDROCHLORIDE, OXYCODONE, ALFUZOSIN HYDROCHLORIDE, ERGOCALCIFEROL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, RIVAROXABAN, |
||||
| 36 | 26560560 |
ZA |
||
Hospitalisation, |
||||
AFLIBERCEPT, |
||||
| 37 | 26560574 |
GB |
2 | |
Hospitalisation, |
||||
CLOZAPINE, |
||||
| 38 | 26560575 |
GB |
1 | |
Hospitalisation, Tachycardia, Sedation complication, Orthostatic hypotension, |
||||
CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, |
||||
| 39 | 26560651 |
EU |
||
Urinary tract obstruction, Death, Hospitalisation, Hypertension, |
||||
TRIPTORELIN, DEGARELIX, LEUPROLIDE ACETATE, |
||||
| 40 | 26560700 |
US |
1 | |
Hospitalisation, |
||||
MEPOLIZUMAB, |
||||
| 41 | 26560702 |
US |
2 | |
Hospitalisation, |
||||
MEPOLIZUMAB, |
||||
| 42 | 26560842 |
US |
72 | 1 |
Ammonia increased, Hepatic cirrhosis, Condition aggravated, Hospitalisation, Confusional state, Therapy interrupted, Product use issue, |
||||
RIFAXIMIN, RIFAXIMIN, |
||||
| 43 | 26560910 |
40 | ||
Hospitalisation, Kidney infection, Treatment noncompliance, Insurance issue, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 44 | 26561513 |
GB |
1 | |
Hospitalisation, |
||||
| 45 | 26561530 |
US |
56 | 1 |
Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 46 | 26561544 |
US |
83 | 1 |
Death, Hospitalisation, |
||||
IBRUTINIB, IBRUTINIB, |
||||
| 47 | 26565733 |
2 | ||
Hospitalisation, |
||||
TADALAFIL, |
||||
| 48 | 26565738 |
2 | ||
Cardiac disorder, Therapy interrupted, Hospitalisation, |
||||
EVOLOCUMAB, CARVEDILOL, DONEPEZIL HYDROCHLORIDE, ICOSAPENT ETHYL, MAGNESIUM, SEMAGLUTIDE, ORAL SEMAGLUTIDE, PANTOPRAZOLE, EVOLOCUMAB, ERGOCALCIFEROL, |
||||
| 49 | 26565741 |
1 | ||
Hospitalisation, Therapy interrupted, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, ALLOPURINOL, AMLODIPINE, TACROLIMUS, |
||||
| 50 | 26565959 |
86 | 2 | |
Hospitalisation, Therapy change, |
||||
TAFAMIDIS, |
||||
| 51 | 26565975 |
1 | ||
Hospitalisation, |
||||
TAFAMIDIS, |
||||
| 52 | 26566439 |
1 | ||
Hospitalisation, |
||||
BELZUTIFAN, |
||||
| 53 | 26569513 |
85 | 2 | |
Hospitalisation, |
||||
RUXOLITINIB, RUXOLITINIB, |
||||
| 54 | 26569955 |
|||
Hospitalisation, |
||||
ETANERCEPT, |
||||
| 55 | 26570130 |
65 | 2 | |
Hospitalisation, |
||||
AVACOPAN, AVACOPAN, |
||||
| 56 | 26570284 |
72 | 1 | |
Hospitalisation, |
||||
AVACOPAN, |
||||
| 57 | 26570512 |
70 | 2 | |
Hospitalisation, |
||||
AVACOPAN, |
||||
| 58 | 26550403 |
US |
68 | 2 |
Hospitalisation, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 59 | 26550593 |
GB |
1 | |
Hospitalisation, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 60 | 26550651 |
US |
2 | |
Hospitalisation, Condition aggravated, Knee arthroplasty, |
||||
ADALIMUMAB, ADALIMUMAB, |
||||
| 61 | 26550823 |
US |
2 | |
Hospitalisation, Product dose omission issue, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 62 | 26550903 |
US |
2 | |
Hospitalisation, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 63 | 26550904 |
GB |
2 | |
Hospitalisation, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 64 | 26550926 |
JP |
||
Hospitalisation, |
||||
DAPRODUSTAT, |
||||
| 65 | 26550928 |
JP |
||
Hospitalisation, Haemoglobin abnormal, |
||||
DAPRODUSTAT, |
||||
| 66 | 26550972 |
US |
68 | 2 |
Hospitalisation, |
||||
ETANERCEPT, |
||||
| 67 | 26550976 |
US |
64 | 2 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 68 | 26550979 |
US |
35 | 1 |
Hospitalisation, |
||||
RIFAXIMIN, |
||||
| 69 | 26551046 |
JP |
9 | 2 |
Hospitalisation, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 70 | 26551061 |
TW |
62 | 1 |
Hospitalisation, Off label use, |
||||
BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DARATUMUMAB, THALIDOMIDE, |
||||
| 71 | 26551180 |
US |
1 | |
Fall, Hospitalisation, |
||||
VENETOCLAX, ACALABRUTINIB, |
||||
| 72 | 26551265 |
CA |
73 | 1 |
Hospitalisation, COVID-19, Cells in urine, Disorientation, Gait inability, Haematochezia, Infection, Sensory loss, Migraine, Headache, Therapy change, |
||||
LENALIDOMIDE, |
||||
| 73 | 26551457 |
US |
56 | 2 |
Hospitalisation, |
||||
GLYCEROL PHENYLBUTYRATE, |
||||
| 74 | 26551461 |
US |
63 | 2 |
Seizure, Hospitalisation, Expired product administered, |
||||
INSULIN GLARGINE, INSULIN GLARGINE, INSULIN LISPRO, |
||||
| 75 | 26551664 |
TH |
73 | 2 |
Death, Hospitalisation, |
||||
DENOSUMAB, DENOSUMAB, |
||||
| 76 | 26551681 |
CA |
64 | 2 |
Hospitalisation, Memory impairment, Pain, |
||||
LENALIDOMIDE, |
||||
| 77 | 26551741 |
1 | ||
Hospitalisation, |
||||
LENALIDOMIDE, |
||||
| 78 | 26551745 |
33 | ||
Hospitalisation, |
||||
BIMEKIZUMAB, |
||||
| 79 | 26552285 |
EU |
2 | |
Sepsis, White blood cell count increased, White blood cell count decreased, Hospitalisation, |
||||
PEMBROLIZUMAB, |
||||
| 80 | 26552579 |
GB |
1 | |
Hospitalisation, |
||||
CLOZAPINE, CLOZAPINE, CLOZAPINE, CLOZAPINE, |
||||
| 81 | 26552772 |
US |
1 | |
Hospitalisation, |
||||
APREMILAST, |
||||
| 82 | 26553051 |
GB |
2 | |
Hospitalisation, |
||||
VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR, |
||||
| 83 | 26553245 |
US |
2 | |
Hospitalisation, Weight increased, Dyspnoea exertional, Fatigue, Photosensitivity reaction, Skin discolouration, |
||||
RUCAPARIB, RUCAPARIB, RUCAPARIB, RUCAPARIB, MAGNESIUM, ERGOCALCIFEROL, METOPROLOL TARTRATE, METOPROLOL, MODAFINIL, |
||||
| 84 | 26553404 |
|||
Hospitalisation, |
||||
BUPRENORPHINE, BUPRENORPHINE, |
||||
| 85 | 26553489 |
US |
37 | 1 |
Hospitalisation, Product use in unapproved indication, |
||||
SPARSENTAN, |
||||
| 86 | 26553527 |
US |
83 | |
Hospitalisation, Intentional dose omission, |
||||
VUTRISIRAN, |
||||
| 87 | 26553532 |
US |
||
Hospitalisation, |
||||
VUTRISIRAN, |
||||
| 88 | 26553645 |
37 | 2 | |
Hospitalisation, Pneumonia, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 89 | 26553654 |
55 | 1 | |
Hospitalisation, Surgery, Blood pressure decreased, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 90 | 26553945 |
US |
53 | |
Hospitalisation, |
||||
PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, |
||||
| 91 | 26554198 |
US |
71 | |
Hospitalisation, |
||||
CEMIPLIMAB-RWLC, |
||||
| 92 | 26554229 |
US |
2 | |
Hospitalisation, Therapeutic procedure, |
||||
CANNABIDIOL, CANNABIDIOL, ATENOLOL, ANTACID TABLETS, SENNOSIDES, SENNA LEAF, SENNA, TROFINETIDE, RUFINAMIDE, CALCIUM CARBONATE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, CLOBAZAM, TOBRAMYCIN, TOBRAMYCIN SOLUTION, TOBRAMYCIN SULFATE, MONTELUKAST SODIUM, FAMOTIDINE, IBUPROFEN, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, LATANOPROST, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, ERYTHROMYCIN, POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, BACITRACIN, BACITRACIN ZINC, CETIRIZINE HYDROCHLORIDE, SIMETHICONE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, HEPARIN SODIUM, MOMETASONE, DORZOLAMIDE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 93 | 26554320 |
US |
64 | 1 |
Hospitalisation, Therapy cessation, |
||||
RIFAXIMIN, |
||||
| 94 | 26554592 |
US |
1 | |
Hospitalisation, |
||||
PRALSETINIB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ONDANSETRON HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, METOCLOPRAMIDE HYDROCHLORIDE, VALSARTAN, VALSARTAN ORAL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, |
||||
| 95 | 26554653 |
US |
1 | |
Hospitalisation, |
||||
OLUTASIDENIB, |
||||
| 96 | 26554654 |
US |
1 | |
Hospitalisation, |
||||
CANNABIDIOL, CANNABIDIOL, |
||||
| 97 | 26554662 |
US |
||
Hospitalisation, |
||||
IXEKIZUMAB, |
||||
| 98 | 26554986 |
JP |
||
Hospitalisation, Injection site haemorrhage, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 99 | 26555020 |
US |
52 | 1 |
Hospitalisation, |
||||
PEGLOTICASE, |
||||
| 100 | 26555036 |
US |
67 | |
Hospitalisation, Chills, Diarrhoea, |
||||
FECAL MICROBIOTA SPORES, LIVE-BRPK, FECAL MICROBIOTA SPORES, LIVE-BRPK, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28